ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergNo recent work listed

Luitpold Valentin Distel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8040-3226; OpenAlex author ID A5105405068. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 2

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper

Papers 2

Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Last author DOI 10.3892/ol.2017.7523 ↗
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. Last author DOI 10.1371/journal.pone.0130277 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rainer Fietkau · 2 shared papers, 2015–2018 · strength 0.13
- Paper Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with io… DOI 10.3892/ol.2017.7523 ↗
- Paper Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreat… DOI 10.1371/journal.pone.0130277 ↗
Markus Hecht · 2 shared papers, 2015–2018 · strength 0.13
- Paper Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with io… DOI 10.3892/ol.2017.7523 ↗
- Paper Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreat… DOI 10.1371/journal.pone.0130277 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.